Sernova and Seraxis agree merger to create BetaNova Biotherapeutics
Sernova and Seraxis have entered into a definitive merger agreement to create BetaNova Biotherapeutics, a new clinical-stage company focused on type 1 diabetes islet-cell replacement therapies.
The merger combines Sernova's Cell Pouch bio-hybrid organ platform with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturing capabilities.
Sernova and Seraxis shareholders are each expected to own approximately 50% of BetaNova, while a US$10 million financing is intended to support development of SR-02 and SR-03 and preparations for a potential Nasdaq listing.
Field | Content |
Alert Type | Deal |
Companies | Sernova Biotherapeutics; Seraxis Holdings |
Deal Type | Definitive merger agreement |
Asset or Company | BetaNova Biotherapeutics |
Therapy Area(s) | Type 1 diabetes; regenerative medicine |
Technology or Modality | Islet-cell replacement; stem cell-derived pancreatic islet cells; Cell Pouch bio-hybrid organ |
Deal Value | US$10 million concurrent non-brokered convertible note financing; merger consideration structured so Sernova and Seraxis shareholders are each expected to own approximately 50% of BetaNova |
Geography | United States; Canada |
What Happened | Sernova and Seraxis entered into a definitive merger agreement to combine their businesses and technologies into a new company, BetaNova Biotherapeutics. |
Why It Matters | The transaction brings together complementary islet-cell replacement technologies, development infrastructure and manufacturing capabilities in a single company focused on type 1 diabetes. |
Supporting Context | BetaNova plans to advance SR-02 into a Phase 1/2 trial in type 1 diabetes, with first patient dosing expected in the first quarter of 2027, while SR-03 is being developed as a next-generation gene-edited immune-evasive islet-cell therapy. |
Strategic Rationale | The merger combines Sernova's implantable Cell Pouch platform with Seraxis' stem cell-derived islet-cell technology and cGMP manufacturing to create an integrated regenerative-medicine company. |
Potential Impact | If successful, the combined platform could advance cell-replacement approaches intended to restore insulin-producing function in people with type 1 diabetes. |
Key Takeaway | Sernova and Seraxis are combining to form BetaNova Biotherapeutics, creating an integrated type 1 diabetes cell-therapy company backed by a US$10 million financing. |
What to Watch | Shareholder approval and expected merger closing in November 2026, followed by planned SR-02 clinical dosing and potential Nasdaq listing preparations in 2027. |
Primary Source | Sernova Biotherapeutics |
Relevant Date | 8 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare